Background: Concomitant chemoradiotherapy is an effective treatment modality for advanced head and neck cancer, but improved regimens are needed. We sought to define the toxicities, recommended phase II dose, and outcome of a combination chemotherapy regimen with concomitant hyperfractionated radiotherapy in patients with poor prognosis cancers of the head and neck, including those having received prior curative intent radiotherapy.
Introduction
Head and neck cancer was predicted to affect 41,400 people in the US in 1998 causing over 12,000 deaths [1] . Despite the readily identifiable risk factors of cigarette smoking and alcohol use, and despite the potential to modify these risk factors in a population, the worldwide incidence of this disease has not been decreasing. Early stage (I and II) head and neck cancer (HNC) represents the minority of new cases and can generally be treated for cure with radiation or surgery. Locoregionally advanced HNC represents the majority of cases and is much more difficult to treat. Long-term survival for surgically resectable advanced stage patients has ranged from 20%-40% and for unresectable patients even lower [2] . Over the past decade it has been clearly demonstrated in numerous randomized studies, reviews, and in several meta-analyses that concomitant chemoradiotherapy for unresectable patients improves survival over RT alone [3] [4] [5] [6] . More recently, improved outcome has been strongly suggested even for resectable patients [7] [8] [9] [10] , although no randomized study of chemoradiotherapy versus surgery (with or without radiotherapy) yet exists. As suggested by these studies, in the resectable setting, aggressive combined modality therapy for stage IV patients can be expected to lead to a 40%-60% long-term cure rate, with surgery used only for salvage or for removal of clinically involved lymph nodes.
We have previously published our results of a phase I study utilizing paclitaxel by continuous infusion, 5-FU, and hydroxyurea with granulocyte colony stimulating factor (G-CSF) support and twice daily (bid) radiotherapy (XRT) for patients with poor prognosis cancer of the head and neck [11] . That regimen built on our previous regimen of cisplatin with 5-FU, hydroxyurea, and bid XRT (CFHX) [9] . The CFHX regimen resulted in extremely high rates of locoregional control, but toxicity was prohibitive. Our goal was to substitute a more tolerable, radiosensitizing and systemically active drug in place of cisplatin. We now report on a subsequent phase I study utilizing the same TFHX regimen with paclitaxel given as a one-hour infusion on day 1. This modification was made for three reasons. 1) In the phase I study with prolonged infusion paclitaxel, radiosensitizing doses of paclitaxel were achieved, but in only 65% of patients. The peak concentrations achievable with one hour infusion would thus ensure that radiosensitizing concentrations of paclitaxel would be present during each cycle of chemotherapy for at least some of the fractions of RT. Weekly short infusion schedules may provide radiosensitization on more than just the day of infusion by cell cycle arrest in the radiosensitive G2/M phase and other mechanisms [12, 13] . 2) We sought to increase the paclitaxel dose by minimizing the hematologic toxicity and mucositis seen with prolonged paclitaxel infusions with the goal of achieving a higher paclitaxel dose for systemic cancer treatment. 3) Additionally, we sought to give paclitaxel on a more practical schedule.
Both 5-FU and hydroxyurea have shown independent clinical evidence of radiosensitization in HNC, and there is in vitro and in vivo evidence of addiditve or synergistic activity of these two drugs [14] Hydroxyurea modulates 5-FU by depleting deoxyuridine monophosphate (dUMP). This enhances the binding of 5-fluorodeoxyuridine monophosphate (5-FdUMP) to its target enzyme, thymidylate synthase, enhancing the activity of 5-FU.
This regimen requires the radiation to be administered on a split course schedule. Despite evidence that administration of single daily conventional sized fractions with a split course (or treatment delay) leads to adverse outcome, this has clearly not been the case with aggressive concomitant chemoradiotherapy strategies [8] [9] [10] [15] [16] [17] [18] .
Unresectable locoregional recurrence in previously irradiated HNC patients has generally been treated only with palliative measures. Recently, however, several reports of successful re-irradiation have been published and demonstrate that 10%-30% of suitable patients can be expected to achieve long-term disease free status with a thorough course of re-irradiation [11, [19] [20] [21] . Since these patients are clinically radioresistant based on their locoregional failure following standard dose and single fraction radiotherapy, it is critical to utilize more aggressive radiation and to add radiosensitizing chemotherapy. This has been demonstrated in these studies [20, 21] . Therefore patients who had previously received a full course of radiation were eligible for therapy on this study.
Patients and methods

Eligibility
Patients were eligible for this study if they had histological or cytologic documentation of any malignant neoplasm located in the head and neck area requiring regional radiotherapy. This included patients with primary sites outside of the head who required palliative RT in the head and neck region and patients with non-squamous cell head and neck primaries. As in our previous phase I studies [11, 19] , prior radiotherapy, chemotherapy, and surgery did not preclude enrollment on this protocol, and use of this regimen in the 'adjuvant' setting was allowed, if postoperative therapy was felt to be needed. Previously untreated patients were eligible if they had unresectable disease and an estimated probability of two year survival less than 10%. Measurable disease was not required for protocol entry. Patients with metastatic disease were eligible if the predominant site of disease requiring palliative radiotherapy was in the head and neck area. Thus this heterogenous group of patients were eligible for this phase I study based on the clinical need for head and neck radiotherapy for advanced disease and ineligibility for phase II or III studies.
Performance status ^ 2 was required. Baseline laboratory requirements included: WBC >3000/ul, platelet count 3= 100,000/ul, creatinine $2.0 mg/dl. and SGOTand SGPT $2.5 times the upper limit of normal. This protocol was approved by the University of Chicago Institutional Review Board, and written informed consent was obtained prior to the initiation of protocol treatment. All patients were evaluated by surgical, medical, and radiation oncologists prior to trial entry. Stage, optimal standard therapy, and eligibility for the protocol were determined jointly. Prior to beginning treatment, all patients had uniform staging and preparatory procedures. This included a CT scan of the head, neck and lungs, bone scan, oropharyngeal motility exam, dental evaluation, placement of an implanted central venous catheter, and a gastrostomy tube.
Radiotherapy guidelines
All patients were simulated prior to the start of radiotherapy with an appropriate immobilization device. Appropriate field sizes to treat gross disease and areas of potential microscopic disease were determined at the time of simulation. Initial opposed lateral fields were utilized to treat the primary disease and the neck. The supraclavicular fossae, when indicated, were treated with a separate field. A posterior cord block or midline block was used on the lateral or supraclavicular fields to minimize the chance of overlap on the spinal cord.
Each cycle of radiotherapy consisted of five days of consecutive treatment Patients received twice daily radiotherapy consisting of 150 cGy fractions with a minimum of six hours between fractions.
Previously un-irradiated patients were treated as follows. Anterior neck doses for microscopic disease were 5000-6000 cGy. Boosts were given to the primary areas and areas of gross disease after appropriate field reductions, to a total dose of 6600-7500 cGy. The dose delivered to the supraclavicular fossae was 4500-5100 cGy for microscopic disease. For gross disease a total of 6600-7400 cGy was delivered. The dose to the posterior neck was 4500-6000 cGy for microscopic disease and 6600-7400 cGy for gross disease. Electrons were used to boost the posterior neck to minimize the dose to the spinal cord to $ 4000 cGy.
Previously treated patients were treated more heterogeneously, based on the constraints of prior therapy. In general, gross disease received 7100-7500 cGy. Areas considered at risk for microscopic disease received 4500-6000 cGy.
Chemotherapy
Each cycle of chemoradiotherapy lasted two weeks with treatment given on days 1-6 (Table 1) . Patients were admitted to the hospital on Sunday night, at which time they received a dose of oral hydroxyurea and began a 120-hour continuous infusion of 5-FU (administered in 1000 cc D 5 W daily). Paclitaxel was administered as a one-hour infusion on day 2 (after the first dose of radiation) via the dose escalation strategy outlined below. Dexamethasone 10 mg was given orally 12 and 1 hours prior toTaxol and Benadryl, 25 mg, was given by i.v. push 30 min prior to Taxol. Paclitaxel and 5-FU were infused though indwelling double lumen implanted tunneled catheters. Oral hydroxyurea was given twice daily on Monday through Friday with the first daily dose given two hours prior to the first daily dose of radiotherapy. Patients unable to swallow hydroxyurea received it through a gastrostomy tube. Specific chemotherapy dosages for the 6 dose levels are given in Table 2 .
Supportive care
All patients received granulocyte colony stimulating factor between days 7 and 13 at a dose of 5 ug/kg subcutaneously. All patients were seen by a dietician in the hospital and were begun on supplemental gastrostomy tube feedings when their oral caloric intake became inadequate. Daily hydration with 1-2 liters of normal saline was given at home or as an outpatient for six days after chemotherapy. Electrolytes were repleted as necessary. Oral hygiene was maintained with an antifungal mouth rinse, saline mouth rinse, and a combination of lidocaine. diphenhydramine, and sodium bicarbonate mouth rinse. Vigilant attention was paid to skin care in the radiation field. A water based, aloe containing gel was applied after the final daily treatment and removed prior to the first daily treatment. When moist desquamation occurred, a hydrogel barrier dressing was applied after each treatment. Diarrhea was managed with kaolin-pectin suspension or loperamide. Patients were seen at least once during their off-treatment week in the outpatient clinic.
Dose escalation strategy
Patients were treated in cohorts of at least three to six individuals. If no more than one patient developed dose limiting toxicity (DLT), the paclitaxel dose was increased in the subsequent cohort. If two patients developed toxicity, three additional patients were treated, for a total of at least six. If three patients experienced DLT, that dose level was considered maximum administered dose (MAD). The maximum tolerated dose (MTD) and thus the recommended phase II dose (RPTD) level was to be one dose level below the MAD. The dose levels and number of patients per cohort are given in Table 2 . The initial strategy was to keep a fixed level of 5-FU and hydroxyurea with dose escalation of the paclitaxel. After dose level 3 was reached and tolerated (same doses as in prior TFHX study) 5-FU and hydroxyurea were escalated. This dose level was not tolerated, thus re-escalation of paclitaxel was continued.
Dose-limiting toxicity
Dose-limiting toxicity was defined as follows: hematological toxicity of grade 4 for > 4 days or persisting on day 1 of the next cycle, or the development of a neutropenic fever; mucositis or dermatitis of grade 4 not resolved to ^ grade 3 on day 1 of the next cycle; and any other grade 3 toxicity (except nausea, vomiting and alopecia). Failure to receive the full dose of chemotherapy within 24 hours of the scheduled time during the first two cycles (including day 1 of cycle 3) also constituted DLT. DLT's encountered during the first two cycles only were considered for dose escalation purposes. Cumulative toxicities from all cycles were taken into account when determining the RPTD.
Other study endpoints
The primary endpoint was description of toxicity and definition of RPTD. Response rate, time to progression, and survival were evaluated as secondary endpoints. Complete response (CR) was defined as the complete disappearance of all detectable disease as assessed four to eight weeks after completion of therapy. Biopsy or surgical confirmation was attempted. Partial Response (PR) was defined as reduction by at least 50% in the sum of the products of the longest perpendicular diameters of all measurable tumor masses. Progressive disease (PD) was defined as an increase by > 25% of the products of the perpendicular diameters of a tumor lesion or the appearance of new lesions.
Patients with stable disease (SD) met neither the criterion for PR or PD. Time to progression was measured from the first day of therapy until the documentation of new tumor lesions, increase in the size of previously known sites of disease, or death from disease or toxicity.
Patients were censored if they were alive or died without progression. Survival was measured from the first day of therapy until death. Death from toxicity was counted as a treatment failure in all survival analyses. The actuarial method of Kaplan-Meier was used to calculate survival.
Dose modifications
Guidelines for dose modifications were as follows, for grade 4 mucositis, dermatitis or diarrhea exceeding seven days duration or persisting on day one of the next cycle, the 5-FU was decreased by 25% and the paclitaxel by one dose level. There was no treatment delay for dermatitis, mucositis, or diarrhea. For aWBC of 1.0-1.9/ul or a platelet count of 50,000-74,000/ul on day one of each cycle, paclitaxel was decreased by one dose level and hydroxyurea by 50% of the dose. For WBC of less than 1.0/ul or a platelet count of <50,000/ul on day one of any cycle, no paclitaxel or hydroxyurea were given but 5-FU was given at full dose. A cycle could be postponed in the presence of a fever greater than 38 °C or other clinically apparent infection or at the discretion of the treating physician.
Results
This study accrued 54 patients from November 1995 until December 1997. There is a median of 23 months follow-up for surviving patients. Patient characteristics are detailed in Tables 3-5 . The majority of patients were male with a median age of 59 and performance status of 1. At the time of study entry, metastatic disease was proven in nine patients. Metastases were suspected in 10 patients and later proven in at least 4. Thirty-four of the fifty-four patients had recurrent disease and had prior therapy consisting of radiation, surgery, or chemotherapy. Two additional patients had prior chemotherapy (26) 16 (30) 24 (44) 14 (26) 44 (81) 10 (19) 45 (83) 9 a (17) 48 (89) 6" (11) 18 (33) 16 (30) 8 (15) 5 (9) 3 (6) 3 (6) 1 (2) 50 (93) 4 (7) 34 (65) 20 c (35) a Additional 10 with suspected metastases, later proven in 4. b Adeno-parotid (2), adenoid cystic tongue (1), mucoepidermoid parotid (1), anaplastic thyroid (1), esophagus (1). c Reasons for poor prognosis eligibility: metastatic disease-proven (4), suspected (6) (later confirmed in 3); non-squamous or non-head and neck (3); prior malignancy/coexisting morbidity/extremely poor prognosis (5); prior chemotherapy for newly diagnosed HNC (2).
at an outside institution for first presentation of tumor, then switched their care to University of Chicago. Twenty-four patients (44%) had received prior radiotherapy either alone or in combination with surgery and/or chemotherapy. In these 24 patients a median of 6871 Gy had been previously delivered to the primary tumor.
Dose escalation and RPTD
The dose escalation scheme is detailed in Table 2 . After dose levels 1, 2 and 3 were completed without reaching maximum tolerated dose, we escalated the dose of hydroxyurea to 1000 mg b.i.d. and 5-FU to 800 mg/m 2 per day. These are the doses of the original FHX regimen that had been previously used alone and with cisplatin [8, 19, 22] . In our previous phase I study of TFHX we were unable to give these doses along with Median = 6871 cGy a Three cases were not recurrent. b Eligibility based on metastatic disease: documented (4), suspected (6) (later confirmed in 3 to date), non-squamous/poor prognosis (3), prior malignancy/coexisting morbidity/extremely poor prognosis (5). 1 (1) 1 (1) 1 (1) 2 (1) 6(4)
Includes the 18 patients who were not previously treated with surgery, XRT, or chemotherapy. Excludes one esophageal patient. Number in parentheses indicate number with proven or suspected metastatic disease.
paclitaxel at 100 mg/m 2 by 120-hour infusion [11] . Thus we attempted this escalation using this new schedule of paclitaxel in an attempt to add the paclitaxel to the previously described FHX regimen. Although only two of seven patients had dose limiting toxicities (as defined in cycles 1 and 2), five of seven did develop grade 4 mucositis or dermatitis on later cycles, and this dose level was not considered feasible. We therefore returned to dose escalation of paclitaxel. Six patients were treated at 120 mg/m 2 with no dose limiting toxicity, although again cumulative grade 4 mucositis or dermatitis occurred in five of six patients. This was recognized after two patients had begun the next paclitaxel dose level (dose level 150 mg/m 2 ). These 2 patients had their paclitaxel doses reduced to 100 mg/m 2 , and 21 additional patients were treated with the recommended dose of paclitaxel, 100 mg/m 2 . Three of these twenty-one patients developed dose limiting toxicity and therefore this regimen was accepted and has since been tested in a full phase II trial. The final RPTD was dose level 3: 5-FU 600 mg/m 2 /day x 5 days (days 1-5), hydroxyurea 500 mg/m 2 b.i.d. x 11 doses total (days 1-6), and paclitaxel 100 mg/m 2 over 1 hour on day 2, with twice daily RTat 1.5 Gy per fraction (days 2-6).
Toxicities Hematologic
Hematologic toxicity was very mild. G-CSF was used prophylactically based on the results of our previous Two re-irradiation and three first irradiation patients did not complete at least four cycles of planned therapy and are not included in toxicity data here. planned cycles of treatment. Thus 59% of all patients experienced grade 3 or 4 dermatitis. Grade 3 mucositis occurred in 55% of patients and grade 4 in 24% of all patients completing all planned cycles of treatment. Other non-hematologic toxicities were rare, with one patient experiencing grade 4 diarrhea and three patients experiencing grade 3 nausea and vomiting. A total of six patients died either on treatment or from possible treatment related toxicities. Two of these six patients died on study. One extremely heavily pretreated patient died at home of cardiopulmonary arrest of unknown cause after two cycles. The second patient died after one cycle from a probable pulmonary embolus. One other patient with anaplastic thyroid carcinoma died two weeks after completion of therapy. Three additional patients died after completion of therapy from possible treatment related causes; two with carotid artery rupture eight and ten months after starting treatment, both without other evidence of disease; one other of local complications including fistula and infection due to soft tissue necrosis and self-mutilation.
In our previous study we noted that severe mucositis might be less common in patients undergoing re-irradiation and that grade 4 dermatitis was equally common in re-irradiation and first time radiation patients. In this study, grade 4 mucositis occurred equally between reirradiation and first time radiation patients. Grade 4 dermatitis was more common in re-irradiation patients in this study.
Many patients began this study nutritionally impaired and all patients had a gastrostomy tube placed prior to beginning therapy. Despite aggressive enteral feeding and dietitian counseling and support, patients lost a median of 8% of their pre-therapy body weight while on therapy. Twelve percent of patients lost > fifteen percent of their pre-treatment body weight while on study. The median maximal decrease in serum albumin was 21%.
phase I regimen of TFHX with continuous infusion paclitaxel. In that regimen 10 of 55 patients developed grade 4 neutropenia and 9 of these 10 patients experienced 13 episodes of neutropenic fever [11] . In the current regimen, however, only one patient developed grade 3 and one grade 4 neutropenia. We have since omitted the use of prophylactic G-CSF in this regimen [23] . Grade 3 thrombocytopenia occurred in only one patient and no grade 4 thrombocytopenia occurred. Blood transfusions (median of 2.5 units) were required in 22 (41%) patients.
Non-hematologic toxicities
Non-hematologic toxicities are shown in Table 6 . Table 7 details these toxicities for the 24 re-irradiation patients and the 30 patients receiving a first course of therapy. Grade 3 and 4 dermatitis and mucositis were cumulative as demonstrated by the predominance of this toxicity in cycles 3, 4 and 5. Grade 3 dermatitis occurred in 31% and grade 4 in 29% of patients who completed all Table 8 details parameters of chemotherapy and radiation dose intensity. As noted, patients received nearly all intended cycles of chemotherapy and 83% of patients received at least 80% of drug dose intensity (63% of patients received 100%). Dose reductions or delays were required in 33% of patients but only 12% of all cycles. This was less common at the RPTD. Median delivered radiation dose was 7300 cGy (mean 6737, range 1400-7500 cGy). Five patients failed to complete treatment. Two died on study, and one each refused further therapy after one and three cycles, and the other sought therapy closer to home after two cycles but completed therapy with radiation alone at another institution.
Treatment intensity
Response
Tables 7 and 9 detail responses. We recorded 'clinical' responses based on examination including palpation and inspection of the oral cavity, visible pharynx, and neck Table 9 In field responses in 27 patients treated at phase II dose levels. Nine patients overall were evaluated for out of field responses. Four of these patients were unevaluable. Of the remaining five, one had a PR, one stable disease, and three progression. Fifteen of twenty-seven patients were unevaluable either because treatment was administered after surgery, patient refused, patient was too sick for re-evaluation, or disease progression was noted prior to re-evaluation.
along with direct endoscopic inspection when possible. 'Radiological' response was based on CT scans performed four to six weeks post-therapy. Biopsy results constituted 'pathological' response and were obtained whenever possible, which occurred in nearly half of the patients. Clinical complete response was achieved in 82% of evaluable patients (n = 33). It should be noted, however, that 39% of patients were unevaluable for clinical response either because they were treated in the adjuvant setting or for other reasons. We examined the utility of post-treatment CT scan in this setting. Correlation between CTscan and clinical or pathological findings were poor, although the CT scan did provide useful information to guide post-treatment biopsies as well as information regarding airway patency and other anatomical detail. Half of all patients underwent post-treatment biopsy. The other half did not undergo biopsy either because they were treated in the adjuvant setting (11), they refused biopsy [7] , death or morbidity prevented biopsy (4), or locoregional or distant progression precluded the need for biopsy (6) . Of the 26 patients who underwent biopsy, 24 (92%) were noted to have a complete pathological response. We assessed response in the 27 patients treated at the recommended phase II dose levels ( Table 9 ). The response rates in the 27 patients treated at phase I dose levels and 27 patients at the phase II dose levels were identical (92%). Additionally, response was equivalent between re-irradiated patients and first-time radiation patients.
Nine patients had known metastatic disease that was evaluated post-therapy. One patient had a partial out of field response, one had stable disease, three had progression and four were unevaluable.
Survival
The two-year overall survival was 45%. Twenty-two patients remain alive and well from 11-39 months following treatment. After developing lung metastases, two patients are alive with disease 18 and 22 months after treatment without any evidence of local/regional recurrence. Twenty-one patients are dead of disease. One patient died of intercurrent disease and six patients died of an event related to acute or chronic toxicities of treatment. An additional two patients died of a second malignancy (lung cancer). The two-year overall progression-free survival was 43%. The local/regional control at two years was 65%.
Discussion
This study established the feasibility and activity of TFHX given on a modified schedule from our previous regimen [11] , The final RPTD for this combination is: 5-FU 600 mg/m 2 per day for 5 days (days 1-5); hydroxyurea 500 mg orally twice daily x 11 doses total (days 1-6); paclitaxel 100 mg/m 2 per day over 1 hour on day 2 (first day of radiation each cycle); and radiation 1.5 Gy given twice daily (days 2-6). G-CSF was given on day 7-13 at a dose of 5 ug/kg subcutaneously.
Preclinical studies of paclitaxel with concomitant radiotherapy in cell lines have demonstrated additive or synergistic effects. The degree of radio-enhancement may indeed be related to dose or schedule, although the optimal dose, timing and schedule are not clear from preclinical studies [12, 13, [24] [25] [26] [27] [28] . Several investigators have demonstrated the feasibility of giving radiosensitizing doses of paclitaxel, by short infusion, 24-hour infusion, or longer infusions, with conventional or hyperfractionated RT [12, 13, 25, 26, [29] [30] [31] [32] . While toxicities may be increased, response rate and survival appear promising. Combination chemotherapy with paclitaxel and carboplatin or cisplatin has been shown to be feasible in several studies [33] [34] [35] [36] . Our approach in the development of this regimen was to incorporate paclitaxel into our previously demonstrated effective regimen of FHX [8, 9, 22] as we had in our prior trial [11] . These trials showed high survival rates (62% five years [8] , and 55% three years [9] ) in stage IV patients despite the need for scheduled treatment interruptions. In this trial, however, we altered the schedule from 120-hour infusion to 1-hour infusion and added G-CSF in an attempt to improve toxicity and locoregional or distant control. These schedules are being further assessed in subsequent phase II trials of both 120-hour and 1-hour infusion.
In our previously published TFHX regimen (120-hour infusion), plasma paclitaxel concentrations greater than 10 nmol/1 was achieved in 65% of patients who received paclitaxel 100 mg/m 2 over 120 hours [11] . Because preclinical models have suggested that a concentration 10 nmol/1 are required for radiosensitization, we altered this regimen to give full dose of paclitaxel over one hour, thereby assuring exposure to radiosensitizing doses of this drug for at least some fractions of RT. Induction of G 2 /M arrest may afford radiosensitization for more than just the 24-48 hours during which radiosensitizing dose levels are achieved. Additionally this change simplified the regimen and made it somewhat more practical and cheaper to administer. A secondary goal of this maneuver was to attempt to increase the paclitaxel to a higher dose. We were unable to increase the paclitaxel dose, although the dose intensity, 50 mg/m 2 per week, is systemically active in this disease.
Continuous infusion paclitaxel is generally associated with more neutropenia and mucositis than shorter infusion paclitaxel. We compared hematologic and nonhematologic toxicities between the continuous infusion and one-hour regimens. Although patients were not randomly distributed, patient characteristics were nearly identical in both studies [11] . Neutropenia and thrombocytopenia were indeed less common with the bolus paclitaxel regimen; however, severe mucositis was not less common with the bolus regimen and in fact may have been slightly more common with the one hour infusion. We subsequently have tested this regimen in the phase II setting in which we utilized G-CSF only for those patients who developed severe neutropenia.
We analyzed non-hematologic toxicities as a function of prior radiotherapy. Mucositis was only minimally increased in previously irradiated patients. This contrasted with our prior study in which mucositis was less common in previously irradiated patients. Dermatitis was slightly was more severe in previously irradiated patients in this study.
The 54 patients treated on this study were an extremely poor prognosis group. Thirty-four had recurrent cancer and twenty-four had a prior full course of RT. Metastatic disease was present in at least nine patients at diagnosis. Despite these poor prognostic features, we found this regimen to be feasible. Chemotherapy drugs were given at near full dose intensity and the median dose of RT was 7300 cGy. Two patients died on study and only three others failed to complete the therapy.
Clearly there are limitations as to the interpretability of response and survival in such a heterogenous group treated on a phase I-II study. Preliminary survival data from this study of patients, most of who were treated with curative intent, however, supports the principal that prior aggressive therapy does not preclude a second attempt at cure. We and others have previously demonstrated that patients who have had a full course of radiation can achieve long-term remission or cure with a second full course of radiation given with concomitant radiosensitizing chemotherapy [19] [20] [21] . The two-year overall survival of 45% is preliminary and needs to be interpreted in light of the patient population, but has encouraged us to continue to pursue aggressive therapy in poor prognosis patients, who are informed of the potential limitations and toxicities of this treatment. The survival outcome here is comparable or better to the 32% two-year survival seen in the phase I study of 120-hour paclitaxel, TFHX regimen, in a similar poor prognosis group of patients [11] .
We have again demonstrated that a prior full course of radiotherapy does not necessarily preclude a second full course of radiotherapy for patients in an otherwise desperate situation. Acute toxicities in re-irradiation patients were comparable to those that occurred in patients receiving the first course of radiotherapy. Chronic toxicities are currently being assessed.
In conclusion, the regimen of paclitaxel (one-hour), 5-FU, hydroxyurea and twice daily RT was feasible. Chemotherapy and radiotherapy were given at 80% or greater dose intensity in most patients. With good supportive care, only two deaths occurred on treatment. We demonstrated the feasibility and efficacy of a full course of re-irradiation. The recommended phase II dose, currently being tested in the phase II setting, is 5-FU 600 mg/m 2 per day x 5 days (days 1-5), hydroxyurea 500 mg orally twice for 11 doses beginning the night before RT (days 1-6), paclitaxel 100 mg/m 2 over 1 hour given after the first radiotherapy dose on day 2, and RT 1.5 Gy b.i.d. for 5 days (days 2-6) given every other week for 5 treatment weeks. Although the additive role of paclitaxel is unmeasurable, the response rate in this poor prognosis group is excellent and long term survival is demonstrated in both previously unirradiated and previously irradiated patients. Evaluation of this regimen in a phase II study is currently in progress.
